Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema 1‑year results from the Japan subgroup of the phase 3 YOSEMITE trial /

Hasonló tételek

• Faricimab Treat-and-Extend for Diabetic Macular Edema Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials /
  Szerző: Wong Tien Y., et al.
  Megjelent: (2024)
• Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE) two randomised, double-masked, phase 3 trials /
  Szerző: Wykoff Charles C., et al.
  Megjelent: (2022)
• Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE) two randomised, double-masked, phase 3, non-inferiority trials /
  Szerző: Heier Jeffrey S., et al.
  Megjelent: (2022)
• Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion. 72-Week Results from the BALATON and COMINO Trials
  Szerző: Danzig Carl J, et al.
  Megjelent: (2025)
• Investigation of the chemical durability and effectiveness of textile products with silver coating
  Szerző: Fuderer Dalma, et al.
  Megjelent: (2017)